These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 8093825)

  • 1. T-cells and psychopathology in schizophrenia: relationship to the outcome of neuroleptic therapy.
    Müller N; Hofschuster E; Ackenheil M; Eckstein R
    Acta Psychiatr Scand; 1993 Jan; 87(1):66-71. PubMed ID: 8093825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of Ginkgo biloba extract added to haloperidol on peripheral T cell subsets in drug-free schizophrenia: a double-blind, placebo-controlled trial.
    Zhang XY; Zhou DF; Cao LY; Wu GY
    Psychopharmacology (Berl); 2006 Sep; 188(1):12-7. PubMed ID: 16906395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The predictive value of psychopathological subclassifications for the neuroleptic treatment outcome in schizophrenia.
    Jarema M; Kacperczyk J; Kruszynski S
    Psychopathology; 1991; 24(3):141-6. PubMed ID: 1684443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cellular immunity in schizophrenic patients before and during neuroleptic treatment.
    Müller N; Ackenheil M; Hofschuster E; Mempel W; Eckstein R
    Psychiatry Res; 1991 May; 37(2):147-60. PubMed ID: 1678892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Peripheral blood T-lymphocyte and T-lymphocyte subset ratios before and after treatment in schizophrenia patients not taking antipsychotic medication].
    Baskak SC; Ozsan H; Baskak B; Devrimci Ozgüven H; Kinikli G
    Turk Psikiyatri Derg; 2008; 19(1):5-12. PubMed ID: 18330738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T-cell subsets in schizophrenia: a comparison between drug-naive first episode patients and chronic schizophrenic patients.
    Sperner-Unterweger B; Whitworth A; Kemmler G; Hilbe W; Thaler J; Weiss G; Fleischhacker WW
    Schizophr Res; 1999 Jul; 38(1):61-70. PubMed ID: 10427611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COX-2 inhibition as a treatment approach in schizophrenia: immunological considerations and clinical effects of celecoxib add-on therapy.
    Müller N; Ulmschneider M; Scheppach C; Schwarz MJ; Ackenheil M; Möller HJ; Gruber R; Riedel M
    Eur Arch Psychiatry Clin Neurosci; 2004 Feb; 254(1):14-22. PubMed ID: 14991374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Schizophrenia and immunity].
    Galinowski A; Levy-Soussan P; Lôo H
    Ann Med Psychol (Paris); 1992; 150(2-3):138-42. PubMed ID: 1364190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relations between movement disorders and psychopathology under predominantly atypical antipsychotic treatment in adolescent patients with schizophrenia.
    Gebhardt S; Härtling F; Hanke M; Theisen FM; von Georgi R; Grant P; Mittendorf M; Martin M; Fleischhaker C; Schulz E; Remschmidt H
    Eur Child Adolesc Psychiatry; 2008 Feb; 17(1):44-53. PubMed ID: 17876506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytokine serum levels, autologous mixed lymphocyte reaction and surface marker analysis in never medicated and chronically medicated schizophrenic patients.
    Theodoropoulou S; Spanakos G; Baxevanis CN; Economou M; Gritzapis AD; Papamichail MP; Stefanis CN
    Schizophr Res; 2001 Jan; 47(1):13-25. PubMed ID: 11163541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential cognitive performances between schizophrenic responders and non-responders to antipsychotics: correlation with course of the illness, psychopathology, attitude to the treatment and antipsychotics doses.
    de Bartolomeis A; Balletta R; Giordano S; Buonaguro EF; Latte G; Iasevoli F
    Psychiatry Res; 2013 Dec; 210(2):387-95. PubMed ID: 23910239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes of immunological functions after acute exacerbation in schizophrenia.
    Sasaki T; Nanko S; Fukuda R; Kawate T; Kunugi H; Kazamatsuri H
    Biol Psychiatry; 1994 Feb; 35(3):173-8. PubMed ID: 7909694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sex differences in plasma homovanillic acid levels in schizophrenia and normal controls: relation to neuroleptic resistance.
    Sumiyoshi T; Hasegawa M; Jayathilake K; Meltzer HY
    Biol Psychiatry; 1997 Mar; 41(5):560-6. PubMed ID: 9046988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The use of canonical correlation analysis for the evaluation of correlation strength between clinical and biological parameters].
    Brusov OS; Koliaskina GI; Kaleda VG; Sekirina TP; Kushner SG; Vasil'eva EF
    Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(1):11-9. PubMed ID: 20436432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of subjective well-being in schizophrenic patients with gait parameters, expert-rated motor disturbances, and psychopathological status.
    Putzhammer A; Perfahl M; Pfeiff L; Hajak G
    Pharmacopsychiatry; 2005 May; 38(3):132-8. PubMed ID: 15902585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Motoric neurological soft signs and psychopathological symptoms in schizophrenic psychoses.
    Jahn T; Hubmann W; Karr M; Mohr F; Schlenker R; Heidenreich T; Cohen R; Schröder J
    Psychiatry Res; 2006 Jun; 142(2-3):191-9. PubMed ID: 16650902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T- and B-lymphocytes in patients with schizophrenia in acute psychotic episode and the course of the treatment.
    Maino K; Gruber R; Riedel M; Seitz N; Schwarz M; Müller N
    Psychiatry Res; 2007 Aug; 152(2-3):173-80. PubMed ID: 17448544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of typical and atypical neuroleptics on mitogen-induced T lymphocyte responsiveness.
    Rapaport MH; McAllister CG; Kirch DG; Pickar D
    Biol Psychiatry; 1991 Apr; 29(7):715-7. PubMed ID: 1711382
    [No Abstract]   [Full Text] [Related]  

  • 19. Idazoxan and response to typical neuroleptics in treatment-resistant schizophrenia. Comparison with the atypical neuroleptic, clozapine.
    Litman RE; Su TP; Potter WZ; Hong WW; Pickar D
    Br J Psychiatry; 1996 May; 168(5):571-9. PubMed ID: 8733795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose bromocriptine in neuroleptic-resistant schizophrenia: a pilot study.
    Wolf MA; Diener JM; Lajeunesse C; Shriqui CL
    Biol Psychiatry; 1992 Jun; 31(11):1166-8. PubMed ID: 1356025
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.